Pathophysiology and management of low high-density lipoprotein cholesterol

American Journal of Cardiology

Volumn 83, Issue 9 B, 1999, Pages

  Rader, Daniel J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; FENOFIBRATE; GEMFIBROZIL;

ATHEROGENESIS; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; CORONARY RISK; DRUG EFFECT; EXERCISE; HUMAN; HYPERCHOLESTEROLEMIA; LIFESTYLE; LIPID METABOLISM; LOW FAT DIET; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SMOKING CESSATION; TREATMENT PLANNING;

EID: 0033551395     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00210-6     Document Type: Conference Paper

References (15)

1. Glueck C.J., Fallat R.W., Millet F., Gartside P., Elston R.C., Go R.C. Familial hyper-alpha-lipoproteinemia studies in eighteen kindreds. Metabolism. 24:1975;1243-1265.
2. Tall A.R. Plasma high-density lipoproteins. Metabolism and relationship to atherogenesis. J Clin Invest. 86:1990;379-384.
3. Rader D.J., Ikewaki K. Unravelling high-density lipoprotein-apolipoprotein metabolism in human mutants and animal models. Curr Opin Lipidol. 7:1996;117-123.
4. Eisenberg S. High-density lipoprotein metabolism. J Lipid Res. 25:1984;1017-1058.
5. Krieger M. The "best" of cholesterols, the "worst" of cholesterols. A tale of two receptors. Proc Natl Acad Sci USA. 95:1998;4077-4080.
6. Badimon J.J., Badimon L., Fuster V. Regression of atherosclerotic lesions by high-density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest. 85:1990;1234-1241.
7. Miyazaki A., Sakuma S., Morikawa W., Takiue T., Miake F., Terano T., Sakai M., Hakamata H., Sakamoto Y.-I., Naito M., Ruan Y., Takahashi K., Ohta T., Horiuchi S. Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol. 15:1995;1882-1888.
8. Canner P.L., Berge K.G., Wenger N.K., Stamler J., Friedman L., Prineas R.J., Friedwald W. Fifteen-year mortality in Coronary Drug Project patients long-term benefit with niacin . J Am Coll Cardiol. 8:1986;1245-1255.
9. Frick M.H., Elo O., Haapa K., Heinonen O.P., Heinsalmi P., Helo P., Huttunen J.K., Kaitaniemi P., Koskinen P., Manninen V., et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 317:1987;1237-1245.
10. Goldbourt U., Behar S., Reicher-Reiss H., Agmon J., Kaplinsky E., Graff E., Kishon Y., Caspi A., Weisbort J., Mandelzweig L., et al. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol. 71:1993;909-915.
11. Rubins H.B., Robins S.J., Iwane M.K., Boden W.E., Elam M.B., Fye C.L., Gordon D.J., Schaefer E.J., Schectman G., Wittes J.T. Rationale and Design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol. Am J Cardiol. 71:1993;45-52.
12. Effects of estrogen or estrogen/progestin regimens on heart disease. Arch Intern Med. 153:1993;1528-1538.
13. Downs J.R., Beere P.A., Whitney E., Clearfield M., Weis S., Rochen J., Stein E.A., Shapiro D.R., Langendorfer A., Gotto A.M. Jr. Design and rationale for the Air Force/Texas Coronary Atherosclerosis Prevention study (AFCAPS/TexCAPS). Am J Cardiol. 80:1997;287-293.
14. Andersson L.O. Pharmacology of apolipoprotein A-I. Curr Opin Lipidol. 8:1997;225-228.
15. Nanjee M.N., Crouse J.R., King J.M., Hovorka R., Rees S.E., Carson E.R., Morgenthaler J.J., Lerch P., Miller N.E. Effects of intravenous infusion of lipid-free apo A-I in humans. Arterioscler Thromb Vasc Biol. 16:1996;1203-1214.